News & Insights

Pharma & Biotech ×
Insights
25th May 2022

Biotech funding in a risk-off climate – does upstream trouble loom for pharma services providers?

Biotech funding is the key driver of innovation in the pharmaceutical industry and is essential in supporting the healthcare ecosystem. More than 80% of drugs marketed by large pharmaceutical companies were discovered and initially developed by biotechs1. Biotech companies also discovered more than 60% of FDA-approved “priority” drugs, which treat life-threatening conditions and offer significant […]

Insights
28th March 2022

The growing impact of Environmental, Social, and Governance (“ESG”) on pharmaceutical supply chains.

The Russian invasion of Ukraine has been touted as the final nail in the coffin of globalisation, confirming the nationalisation of key industries and products. With respect to pharmaceutical manufacturing, this is accelerating a trend which has been ongoing for 10 years, the repatriation of drug manufacturing from Asia to the US and Europe has […]

Insights
23rd February 2022

Discovery CROs: what is the “balanced business model” and how is this valued?

Discovery Contract Research Organisations (“CROs”) essentially provide lab-based discovery services such as medicinal chemistry, biological screening etc to pharma companies and biotech, and this business segment has exploded in size, sophistication and value in recent years and is now a focus of both M&A and PE investment. This is covered in our forthcoming white paper […]

Reports
1st February 2022

Pharma Commercialisation Services Update – February 2022

We are pleased to introduce you to the first of our regular sector updates on the outsourced pharma commercialisation sector.  For some time, Results Healthcare has been producing sector updates and whitepapers on the two other major areas pharmaceutical companies choose to outsource: manufacturing and research. This report focuses on commercialisation, encompassing Healthcare Marketing, Market […]

Insights
19th January 2022

Predictions for Life Sciences Industries for 2022, and no ‘San Francisco’ This Year!

The Covid 19 pandemic continues to have a major impact on the healthcare industry, both positive if you are close to the discovery and provision of treatments for this infection and negative if you are selling certain other drugs, such as antibiotics or providing care services, which have been negatively impacted by this pandemic. However, […]

Insights
10th December 2020

Cell and Gene Therapies: Challenges in Scale-up to Commercial Manufacturing

The cellular therapy and gene therapy fields are undergoing very rapid growth. This includes a large and growing number of products in the development pipeline, and new products with significant sales, including blockbusters, now entering world markets. Billions are being invested in research and commercial development with markets in $10s of billions expected in the […]

Insights
30th May 2020

Biotech share prices in this COVID-19 era and the rollercoaster impact of remdesivir

Although the exact numbers are yet to be known, the virus has claimed nearly 220,000 lives and infected more than 3 million people globally. The COVID-19 outbreak is proving every week to be more of an economic event than a sanitary one. Numerous economic data releases from various countries every week are gloomy and prove […]

Reports
27th May 2020

Generic Pharmaceutical Market: M&A Activity

The global generic pharmaceutical market has experienced robust deal activity over the last 18 months to the end of 2019 but is now contending with the COVID-19 crisis which has had an immediate and unprecedented impact on health systems. It is yet unclear what the long-term general impact on generic drug usage will be, but […]

Insights
20th May 2020

Moderna Coronavirus vaccine trial shows promising early results and the markets move positively

Every week is a roller coaster in the current COVID-19 environment. Most of us spend Sunday evenings preparing ourselves for the upcoming week and hoping for some positive developments on the healthcare, economy, or financial markets’ fronts. Luckily, on Monday, May 18th, Moderna’s coronavirus vaccine trial shed some light at the end of the tunnel […]

Subscribe

We add value by understanding our sectors inside-out, and we release regular industry research and reports on key trends in the technology and healthcare sectors. Fill out the form to start receiving alerts when we publish new content or to follow our latest deals, upcoming events and company updates.

  • This field is for validation purposes and should be left unchanged.